These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 19680161

  • 1. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.
    Huang WF, Tsai YW, Wen YW, Hsiao FY, Kuo KN, Tsai CR.
    Menopause; 2010; 17(1):57-63. PubMed ID: 19680161
    [Abstract] [Full Text] [Related]

  • 2. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
    Lu PY, Hsieh CF, Tsai YW, Huang WF.
    Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
    [Abstract] [Full Text] [Related]

  • 3. Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.
    Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L.
    Calcif Tissue Int; 2010 May; 86(5):335-42. PubMed ID: 20309678
    [Abstract] [Full Text] [Related]

  • 4. Atrial fibrillation in fracture patients treated with oral bisphosphonates.
    Abrahamsen B, Eiken P, Brixen K.
    J Intern Med; 2009 May; 265(5):581-92. PubMed ID: 19141097
    [Abstract] [Full Text] [Related]

  • 5. Compliance of osteoporotic patients with different treatment regimens.
    Segal E, Tamir A, Ish-Shalom S.
    Isr Med Assoc J; 2003 Dec; 5(12):859-62. PubMed ID: 14689753
    [Abstract] [Full Text] [Related]

  • 6. Use of alendronate and risk of incident atrial fibrillation in women.
    Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM.
    Arch Intern Med; 2008 Apr 28; 168(8):826-31. PubMed ID: 18443257
    [Abstract] [Full Text] [Related]

  • 7. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.
    Int J Clin Pharmacol Res; 2004 Apr 28; 24(1):1-10. PubMed ID: 15575171
    [Abstract] [Full Text] [Related]

  • 8. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
    Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR, CORE Investigators.
    J Natl Cancer Inst; 2004 Dec 01; 96(23):1751-61. PubMed ID: 15572757
    [Abstract] [Full Text] [Related]

  • 9. The effect of raloxifene on cardiac autonomic regulation in osteoporotic women.
    Gol M, Baris N, Guneri S, Posaci C.
    Am J Obstet Gynecol; 2006 May 01; 194(5):1249-54. PubMed ID: 16647907
    [Abstract] [Full Text] [Related]

  • 10. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM.
    Clin Ther; 2006 Feb 01; 28(2):236-42. PubMed ID: 16678644
    [Abstract] [Full Text] [Related]

  • 11. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME, Cummings SR, Disch DP, Mershon JL, Dowsett SA, Cauley JA, Martino S.
    Clin Cancer Res; 2006 Sep 01; 12(17):5242-7. PubMed ID: 16951244
    [Abstract] [Full Text] [Related]

  • 12. Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study.
    Chiang CH, Huang CC, Chan WL, Huang PH, Chen TJ, Chung CM, Lin SJ, Chen JW, Leu HB.
    J Bone Miner Res; 2012 Sep 01; 27(9):1951-8. PubMed ID: 22532232
    [Abstract] [Full Text] [Related]

  • 13. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
    Lin TC, Yang CY, Yang YH, Lin SJ.
    J Clin Endocrinol Metab; 2013 Dec 01; 98(12):4717-26. PubMed ID: 24081731
    [Abstract] [Full Text] [Related]

  • 14. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA, Amonkar MM, Hebborn A, Altman R.
    Curr Med Res Opin; 2005 Sep 01; 21(9):1453-60. PubMed ID: 16197664
    [Abstract] [Full Text] [Related]

  • 15. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis.
    Ensrud K, Genazzani AR, Geiger MJ, McNabb M, Dowsett SA, Cox DA, Barrett-Connor E.
    Am J Cardiol; 2006 Feb 15; 97(4):520-7. PubMed ID: 16461049
    [Abstract] [Full Text] [Related]

  • 16. Prescriptions for vitamin D among patients taking antiresorptive agents in Canada.
    Hanley DA, Zhang Q, Meilleur MC, Mavros P, Sen SS.
    Curr Med Res Opin; 2007 Jun 15; 23(6):1473-80. PubMed ID: 17559742
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.
    Curr Med Res Opin; 2008 Mar 15; 24(3):807-13. PubMed ID: 18254988
    [Abstract] [Full Text] [Related]

  • 19. Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
    Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ.
    J Bone Miner Res; 2004 Aug 15; 19(8):1270-5. PubMed ID: 15231013
    [Abstract] [Full Text] [Related]

  • 20. Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene.
    Duvernoy CS, Kulkarni PM, Dowsett SA, Keech CA.
    Menopause; 2005 Aug 15; 12(4):444-52. PubMed ID: 16037760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.